EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes

Paul Gabarre, Roberto Palacios iD, Kevin Perez, Philippe Seksik iD, Benjamin Bonnard, Christopher Loens, Clara Lefranc iD, Jean-Paul Pais de Barros, Louis Anjou, Yanis Tamzali iD, Noël Zahr, Frédéric Jaisser und 1 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0320438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Paul Gabarre und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR, Centre de Recherche des Cordeliers CRC, Team Metabolic Diseases, Diabetes and Comorbidities, Paris, France. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diet, High-Fat, Immunosuppressive Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inserm, Assistance Publique - Hôpitaux de Paris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kidney transplant recipients are prescribed an immunosuppressive therapy (IST) and some of them follow a high fat diet (HFD) despite medical recommendations. Both are frequently associated with gut microbiota changes and metabolic disorders. We aimed at precisely identifying the effect of the IST and the HFD on metabolic parameters and the gut microbiota in mice, and at establishing correlations between the latters.

Methods

8-week-old male mice were treated with IST (a combination of prednisone, mycophenolate mofetil and tacrolimus) or not and were fed HFD or standard chow. Metabolic parameters were measured, and the gut microbiota was explored by the quantification of specific bacterial groups by qPCR and by 16S rDNA sequencing.

Results

The HFD increased insulinemia and decreased the fecal proportion of Bacteroidetes and of Bacteroides . The IST increased systolic blood pressure and the fecal proportion of Escherichia coli . The HFD and the IST administered together resulted in an additive effect on glucose intolerance, high fasting blood glucose, homeostasis model assessment of insulin resistance (HOMA-IR), percentage of fat mass, blood triglyceride, blood cholesterol, and endotoxemia. On the opposite, the HFD and the IST had antagonistic effects on body weight, the proportion of Firmicutes, the Firmicutes/Bacteroidetes ratio, and the proportion of Clostridium leptum , Bifidobacterium , and Lactobacillus in the feces. Finally, we found that the correlations between gut bacterial communities and metabolic consequences of the HFD were altered by the IST.

Conclusion

The IST and the HFD have specific consequences on the gut microbiota and metabolism. We hypothesize that the metabolic consequences are at least partially mediated by IST/HFD-induced dysbiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeDiet, High-FatImmunosuppressive AgentsCardiovascular DiseasesAnimalsMaleMiceHeart Disease Risk FactorsMice, Inbred C57BLInsulin ResistanceFecesBlood GlucosePrednisoneRisk Factors

Substanzen

Immunosuppressive AgentsBlood GlucosePrednisone

Autor:innen und Institutionen

  • INSERM UMR, Centre de Recherche des Cordeliers CRC, Team Metabolic Diseases, Diabetes and Comorbidities, Paris, France.
  • Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
  • Gastro-enterology Department, Centre de Recherche Saint Antoine, Sorbonne Université, INSERM UMRS 938, Assistance Publique - Hôpitaux de Paris APHP, Saint-Antoine Hospital, Paris, France.
  • Lipidomic Analytical Platform, INSERM UMR1231 Université de Bourgogne, Dijon, France.
  • Department of Kidney Transplantation - Nephrology, Assistance Publique - Hôpitaux de Paris APHP, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France.
  • Department of Pharmacology, Assistance Publique - Hôpitaux de Paris AP-HP, INSERM, CIC-1901, Pharmacokinetics and Therapeutic Drug Monitoring Unit, UMR-S Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.

ORCID-Profile: Roberto Palacios, Philippe Seksik, Clara Lefranc, Yanis Tamzali, Jérôme Tourret

Förderung

  • Inserm
  • Assistance Publique - Hôpitaux de Paris

Zitieren

APA

Gabarre, P., Palacios, R., Perez, K., Seksik, P., Bonnard, B., Loens, C., Lefranc, C., de Barros, J. P., Anjou, L., Tamzali, Y., Zahr, N., Jaisser, F., & Tourret, J. (2025). Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes. PLOS ONE. https://doi.org/10.1371/journal.pone.0320438

Vancouver

Gabarre P, Palacios R, Perez K, Seksik P, Bonnard B, Loens C, et al. Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes. PLOS ONE. 2025. doi:10.1371/journal.pone.0320438

BibTeX
@article{Gabarre2025,
  author = {Gabarre, Paul and Palacios, Roberto and Perez, Kevin and Seksik, Philippe and Bonnard, Benjamin and Loens, Christopher and Lefranc, Clara and de Barros, Jean-Paul Pais and Anjou, Louis and Tamzali, Yanis and Zahr, Noël and Jaisser, Frédéric and Tourret, Jérôme},
  title = {Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0320438}
}
Kostenlos starten →